

PRESS RELEASE

Heidelberg Pharma Announces Participation at Various Conferences

Ladenburg, Germany, 17 June 2021 – Heidelberg Pharma AG (FSE: HPHA) today announced that they will present its proprietary ATAC technology at two upcoming scientific events. Heidelberg Pharma is an oncology specialist and the first company to develop the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology, and to advance the biological mode of action of the toxin as a novel therapeutic principle.

[BCMA Targeted Therapies Summit](#) (virtual format)

The inaugural event will bring together the BCMA field to share the latest preclinical data for next generation BCMA therapies and the current challenges for drug developers from a patient perspective.

Date: 21st – 23rd June 2021

Details of the presentation

BCMA-ATAC: Introducing a Novel Mode of Action in Cancer Therapy

Date: 23rd June 2021 at 11:00 am EDT / 05:00 pm CEST

Presenter: Prof. Andreas Pahl, CSO

[9th Antibody Industrial Symposium](#) (virtual format)

This international congress brings together scientists, physicians, policy makers and the industry with a 3-day program on therapeutic antibodies and more.

Date: 22nd – 25th June 2021

Details of the presentation

Amanitin-based Antibody-Drug-Conjugates as New Therapeutic Modalities for Cancer Therapy

Track: Driving Innovative Drugs into Clinical Success, Session II

Date: 24th June 2021 at 02:00 pm CEST

Presenter: Prof. Andreas Pahl, CSO

About Heidelberg Pharma's proprietary ATAC technology

Antibody Drug Conjugates (ADCs) combine the high affinity and specificity of antibodies with the potency of cytotoxic small molecules for the treatment of cancer. Antibody Targeted Amanitin Conjugates (ATACs) are ADCs whose active ingredient is made up of amatoxin molecules. Amatoxins are small bicyclic peptides naturally occurring in the death cap mushroom. They inhibit mRNA transcription by binding to RNA polymerase II, a mechanism that is crucial for the survival of eukaryotic cells. In preclinical testing, ATACs have been shown to be highly efficacious, overcoming frequently encountered resistance mechanisms and combating even quiescent tumor cells.

About Heidelberg Pharma

Heidelberg Pharma AG is a biopharmaceutical company based in Ladenburg, Germany. Heidelberg Pharma is an oncology specialist and the first company to develop the toxin Amanitin into cancer therapies. The proprietary technology platform is being applied to develop the Company's proprietary therapeutic ATACs as well as in third-party collaborations. The proprietary lead candidate HDP-101 is a BCMA ATAC for multiple myeloma and will enter clinical development shortly. HDP-102, a CD37 ATAC for Non-Hodgkin's lymphoma and HDP-103, a PSMA ATAC for metastatic castration-resistant prostate cancer, are in preclinical testing.

Heidelberg Pharma AG is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol HPHA. More information is available at www.heidelberg-pharma.com.

Contact

Heidelberg Pharma AG
Corporate Communications
Sylvia Wimmer
Tel.: +49 89 41313829
E-Mail: investors@hdpharma.com
Gregor-Mendel-Str. 22, 68526 Ladenburg

IR/PR support

MC Services AG
Katja Arnold (CIRO)
Managing Director & Partner
Tel.: +49 89 21022840
Mobil: +49 160 9360 3022
E-Mail: katja.arnold@mc-services.eu

This communication contains certain forward-looking statements relating to the Company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "will", "should", "future", "potential" or similar expressions or by a general discussion of the Company's strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.